PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry – FDA

Опубликовано 3 октября, 201817 декабря, 2018 frozencat

Обновление руководства FDA:

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry

Руководство замещает Adaptive Design Clinical Trials for Drugs and Biologics – 2010.

Рубрики: Блог

Навигация по записям

Предыдущая запись: Определение объема выборки для исследований биоэквивалентности с использованием компьютерного моделирования
Следующая запись: Работа с данными в IBM SPSS: присвоение меток переменным из другого источника

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

DJI 0030
20180813 224437
20170730 151435
DJI 0010
20170803 181008
20170804 195900
  • Influenza (Flu) Antiviral Drugs and Related Information
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • From Our Perspective
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • CDER Pilot Grant Program: Standard Core Clinical Outcome Assessments (COAs) and their Related Endpoints
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Competitive Generic Therapy Approvals
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Human medicines European public assessment report (EPAR): Livmarli, maralixibat chloride, Date of authorisation: 09/12/2022, Revision: 9, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-12
  • Completed PDUFA VI Deliverables
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • How Modeling Was Used to Support the FDA Approval of a Topical Generic Drug Product
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • FDA Adverse Event Reporting System (FAERS) Electronic Submissions
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Office of Infectious Diseases Research Activities
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • How physicians interpret information about prescription drugs in scientific publications vs. promotional pieces
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Annual Licensure Reporting by Wholesale Drug Distributors and Third-Party Logistics Providers
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Check Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Human medicines European public assessment report (EPAR): Velsipity, etrasimod, Date of authorisation: 16/02/2024, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-12
  • Patient-Focused Drug Development: Workshop #2 to Discuss Methodologic and Other Challenges Related to Patient Experience Data - 09/18/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-11 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.